Advertisement
Health in Action

Health in Action The Health in Action section provides a place where groups or individuals who are not represented regularly in a medical journal have a forum to describe the important issues from their perspective. Authors might include patient advocacy groups, healthcare workers, or non-governmental organizations.

See all article types »

The Comparative Oncology Trials Consortium: Using Spontaneously Occurring Cancers in Dogs to Inform the Cancer Drug Development Pathway

  • Ira Gordon,

    Affiliation: Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, United States of America

    X
  • Melissa Paoloni,

    Affiliation: Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America

    X
  • Christina Mazcko,

    Affiliation: Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America

    X
  • Chand Khanna mail

    khannac@mail.nih.gov

    Affiliation: Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America

    X
  • Published: October 13, 2009
  • DOI: 10.1371/journal.pmed.1000161

Reader Comments (1)

Post a new comment on this article

Lack of intratumor heterogeneity

Posted by cmaley on 30 Oct 2009 at 18:51 GMT

genomic instability, and the heterogeneity of both tumor cells and their surrounding microenvironment
http://plosmedicine.org/article/info:doi/10.1371/journal.pmed.1000161#article1.body1.sec2.p1

I think this is a critical issue. Since therapeutic resistance often evolves from selection on the (epi)genetic diversity within the tumor, we should be testing drugs on animal models that have high degrees of intratumor heterogeneity. I agree that the dog spontaneous tumor model is promising.

No competing interests declared.